Whitehawk Therapeutics (WHWK) Equity Average (2011 - 2026)

Whitehawk Therapeutics (WHWK) has 16 years of Equity Average data on file, last reported at $126.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $126.2 million, down 7.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $126.2 million (down 7.92% YoY), and the FY2025 annual result was $94.4 million, up 19.73% from the prior year.
• Equity Average retreated to $126.2 million in Q1 2026 per WHWK's latest filing, from $146.7 million in the prior quarter.
• Over five years, Equity Average peaked at $196.9 million in Q2 2025 and troughed at $60.7 million in Q4 2024.
• A 5-year average of $127.4 million and a median of $130.5 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average soared 961.38% in 2022, then slumped 45.68% in 2024.
• A 5-year view of Equity Average shows it stood at $163.7 million in 2022, then slumped by 31.79% to $111.7 million in 2023, then tumbled by 45.68% to $60.7 million in 2024, then soared by 141.85% to $146.7 million in 2025, then decreased by 13.97% to $126.2 million in 2026.
• Business Quant data shows WHWK's Equity Average at $126.2 million in Q1 2026, $146.7 million in Q4 2025, and $164.6 million in Q3 2025.